ReviewFrontiers in immunology2026
From mechanical adaptation to innate immune reprogramming in osteoarthritis: a load-immunity framework.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a whole-joint disease in which mechanical exposure and low-grade sterile inflammation interact, but their coexistence does not by itself explain why a normally adaptive response becomes self-sustaining. This Mini Review therefore focuses on a narrower question: how do specific loading conditions push joint-resident cells from reversible mechanoadaptation into persistent innate immune dysregulation? We define innate immune reprogramming operationally as a load-induced change in the activation threshold, metabolic state, secretory output, or intercellular behavior of a resident or recruited cell that outlasts the initiating mechanical episode or changes its response to subsequent loading. We organize the evidence into three levels: initiating mechanical events; intracellular amplification through calcium overload, mitochondrial stress, NLRP3, and cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling; and tissue-specific consequences propagated through interactions among chondrocytes, macrophages, fibroblast-like synoviocytes (FLS), subchondral bone cells, and sensory neurons. Piezo1, TRPV4, NLRP3, and cGAS-STING are treated as context-dependent nodes rather than uniformly pathogenic switches. We also distinguish causal preclinical experiments from human association studies and from proposed joint-level networks. Recent evidence that mitochondria-derived extracellular vesicles released by infrapatellar fat pad mesenchymal stromal cells can transfer mitochondrial DNA (mtDNA) to chondrocytes illustrates how mitochondrial danger signals may propagate extracellularly, although its quantitative importance in human OA remains unresolved. Translationally, load correction has the strongest immediate rationale, whereas molecular interventions require tissue-specific delivery, disease-stage selection, pharmacodynamic biomarkers, and preservation of physiological mechanoadaptation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.